Skip to main content
. 2017 Sep 21;6(10):2222–2233. doi: 10.1002/cam4.1156

Table 1.

Basic information of the included studies

Study Country Case (T/C, n) Age (T/C, y) Sex (M/F) Diagnosis Chemotherapy Lentinan Follow‐up
Cai et al. 11 China 30/34 59 (31–82) 47/17 Advanced lung cancer DNR + ADM + CTX + DDP 2 mg, twice a week 8 weeks
Ina et al. 12 Japan 31/37 67/68 48/20 Metastatic/recurrent GC Paclitaxel + S−1 + DDP 2 mg, twice a month 6 years
Guo et al. 13 China 20/20 56 (23–75) 23/17 Lung cancer + GC 5‐FU + ADM + MMC + DNR + DDP 1 mg, twice a week 8 weeks
Ma et al. 14 China 43/42 62.6 ± 5.7 40/45 Advanced GI cancer Javanica oil emulsion 1 mg, twice a week 8 weeks
Yoshino et al. 15 Japan 149/146 73/74 208/87 Unresectable/recurrent GC S‐1 2 mg, once a week 12 months
Nakano et al. 16 Japan 23/22 63/66 34/11 Unresectable/recurrent GC Tegafur + DDP 2 mg, every day 22 months
Ochiai et al. 17 Japan 45/44 60/63 62/27 Advanced/recurrent GC Tegafur + MMC 2 mg, once a week >2 years
Suto et al. 18 Japan 15/16 62/66 21/10 HCC 5‐FU 2 mg, once a week >3 years
Taguchi et al. 19 Japan 111/104 61/59 151/64 Advanced/recurrent GC 5‐FU + MMC 2 mg, once a week >4 years
Wu et al. 20 China 40/40 68 (55–80) 49/31 Advanced GC 5‐FU + DDP + docetaxel 1 mg, twice a week 4 weeks
Wang et al. 21 China 25/25 60/61 30/20 Esophagus cancer Tegafur 1 mg, every 2 days 6 weeks
Wakui et al. 22 Japan 20/22 <80 26/16 Advanced GC and colorectal cancer Tegafur 2 mg, once a week >4 years
Yang et al. 23 China 31/24 60/59 41/14 HCC Epirubicin + HCPT 500 mg, every day 18 months
Li et al. 24 China 40/40 58 (25–70) 48/32 Advanced GC Paclitaxel + 5‐FU + DDP 2 mg, once a week 6 weeks
Pan et al. 25 China 23/20 53 (21–74) 34/9 Advanced lung cancer + GC 5‐FU + ADM + MMC + CTX + VCR 1 mg, twice a week 3 months
Song et al. 26 China 30/30 65 (60–67) 48/12 Advanced lung cancer MMC + VCR + DDP 2 mg, twice a week 8 weeks
Wang et al. 27 China 42/39 >18 65/16 Advanced lung cancer NVP + DDP 1 mg, twice a week 8 weeks

T, treatment group; C, control group; M, male; F, female; GI, gastrointestinal; GC, gastric cancer; HCC, hepatocellular carcinoma; ADM, adriamycin; CTX, cyclophosphamide; DDP, cisplatin; DNR, daunorubicin; 5‐FU, fluorouracil; HCPT, hydroxycamptothecin, MMC, mitomycin C; VCR, vincristine; NVP, vinorelbine.